Proceedings of the National Academy of Sciences · 2018 · 423 citations · 41 references
Life SciencesBiochemistryMedicinal ChemistryCell SignalingDrug DiscoverySignal TransductionProtein DegradationProtein TargetingReceptor Tyrosine Kinase SignalingTyrosine Kinase InhibitorsBruton Tyrosine KinaseBruton's Tyrosine Kinase InhibitorsBtk InhibitorsCooperativityE3 Ubiquitin Ligase Substrate RecognitionSignalingTyrosine Kinase InhibitionTyrosine Kinase Receptors
Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules that simultaneously bind to a target protein and an E3 ligase, thereby leading to ubiquitination and subsequent degradation of the target. They present an exciting opportunity to modulate proteins in a manner independent of enzymatic or signaling activity. As such, they have recently emerged as an attractive mechanism to explore previously "undruggable" targets. Despite this interest, fundamental questions remain regarding the parameters most critical for achieving potency and selectivity. Here we employ a series of biochemical and cellular techniques to investigate requirements for efficient knockdown of Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine kinase essential for B cell maturation. Members of an 11-compound PROTAC library were investigated for their ability to form binary and ternary complexes with BTK and cereblon (CRBN, an E3 ligase component). Results were extended to measure effects on BTK-CRBN cooperative interactions as well as in vitro and in vivo BTK degradation. Our data show that alleviation of steric clashes between BTK and CRBN by modulating PROTAC linker length within this chemical series allows potent BTK degradation in the absence of thermodynamic cooperativity.
41
Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Farida Latif, Kálmán Tory, James R. Gnarra et al. · Science · 1993 · 3K citations
Kathleen M. Sakamoto, Kyung B. Kim, Akiko Kumagai et al. · Proceedings of the National Academy of Sciences · 2001 · 2.5K citations · Full text
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd, Richard R. Furman, Steven Coutré et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text
Medicine, Hematology, Oncology +12
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Krönke, Namrata D. Udeshi, Anupama Narla et al. · Science · 2013 · 1.8K citations · Full text
Medicine, Cell Biology, Oncology +14
Phthalimide conjugation as a strategy for in vivo target protein degradation
Georg E. Winter, Dennis L. Buckley, Joshiawa Paulk et al. · Science · 2015 · 1.7K citations